Oragenics, Inc. Announces Proposed Public Offering

The Company intends to use the net proceeds from the offering to fund the continued development of its ONP002 product candidate and for general corporate purposes and working capital. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2023, and declared effective on January 25, 2023. The offering will be made only by means of a prospectus supple ...